Business Information
The group's principal activities are to conduct research, develop, sale and market branded and generic prescription pharmaceuticals used primarily to treat and manage pain. The group markets branded pharmaceutical products to doctors, drug wholesalers, pharmacies, hospitals, governmental agencies, physicians and other healthcare professionals. The group also markets its generics through customer service activities, chain and independent retail pharmacists. The group's products include percocet(R), percodan(R), zydone(R) , lidoderm(R), morphine sulfate er, morphidex(R) oxymorphone er, oxymorphone ir, hydrocodex tm, oxycodex tm, percodex(TM) and oxycodone er. The group contracts with third parties to provide certain critical services such as manufacturing, warehousing, distribution, customer service, financial functions, certain research and development activities and medical affairs.
|
|
Name |
Title
|
Email
|
| Roger Kimmel | Chmn. | N/A | | Jeremy Goldberg | MD - Corporate Development | N/A | | Joyce Laviscount | Chief Accounting Officer, VP - Financial Operations | N/A | | Nancy Wysenski | COO | N/A | | Bill Newbould | VP - Corporate Communications, Primary Investor Relations Officer | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 909,659 | 137,839 | | 2005 | 820,164 | 202,295 | | 2004 | 615,100 | 143,309
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
